| Title |
Current and emerging treatment options for uveal melanoma
|
|---|---|
| Published in |
Clinical Ophthalmology, August 2013
|
| DOI | 10.2147/opth.s28863 |
| Pubmed ID | |
| Authors |
Patricia Rusa Pereira, Alexandre Nakao Odashiro, Li-Anne Lim, Cristina Miyamoto, Paula L Blanco, Macanori Odashiro, Shawn Maloney, Dominique F De Souza, Miguel N Burnier |
| Abstract |
Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Unfortunately, the current treatment of metastatic UM is limited by the lack of effective systemic therapy. Options for the management of the primary intraocular tumor include radical surgery as well as conservative treatments in order to preserve visual acuity. For metastatic disease, several approaches have been described with no standard method. Nevertheless, median survival after liver metastasis is poor, being around 4-6 months, with a 1-year survival of 10%-15%. In this review, the authors summarize current and promising new treatments for UM. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Netherlands | 1 | 1% |
| Unknown | 93 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 21% |
| Other | 13 | 14% |
| Student > Bachelor | 13 | 14% |
| Student > Master | 10 | 10% |
| Student > Postgraduate | 8 | 8% |
| Other | 14 | 15% |
| Unknown | 18 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 54% |
| Agricultural and Biological Sciences | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Engineering | 4 | 4% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 22 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2022.
All research outputs
#2,685,053
of 25,584,565 outputs
Outputs from Clinical Ophthalmology
#181
of 3,687 outputs
Outputs of similar age
#22,299
of 210,451 outputs
Outputs of similar age from Clinical Ophthalmology
#2
of 95 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,687 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,451 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.